Lancashire and South Cumbria
Formulary
Formulary
6 Endocrine system
06-04-01-01 Ethinylestradiol
| Ethinylestradiol |
|
Formulary
|
Tablets 10micrograms, 50micrograms |
 MHRA: Hormone replacement therapy (HRT): further information on the known increased risk of breast cancer with HRT and its persistence after stopping |
|
Links
- BMS: BMS statement in response to the publication of the updated NICE Menopause guideline (NG23)
- Diabetes UK: Diabetes when you’re unwell
LSCMMG: Diabetes - Choice of Safety Pen Needles and Lancets- LSCMMG: Diabetes - Pen Needles/Lancets
- LSCMMG: Diabetes - Position Statement Safety Needles and Safety Lancets
- LSCMMG: Diabetes Guideline for antihyperglycaemic therapy in adults with type 2 diabetes
- LSCMMG: Diabetes: Recommended meters, strips and devices
- LSCMMG: Estradiol / micronised progesterone (Bijuve) NMR
LSCMMG: GLP-1 patient contract- LSCMMG: Policy for the Provision of Insulin Pumps for Patients with Diabetes Mellitus
- LSCMMG: Trans Female Gender Dysphoria Information Sheet
- LSCMMG: Trans Male Gender Dysphoria Information Sheet
- MHRA: Diabetes and driving
- MHRA: Hormone replacement therapy (HRT): further information on the known increased risk of breast cancer with HRT and its persistence after stopping
- MHRA: Hormone replacement therapy (HRT): further information on the known increased risk of breast cancer with HRT and its persistence after stopping
- MHRA: Hormone replacement therapy (HRT): further information on the known increased risk of breast cancer with HRT and its persistence after stopping
- MHRA: Hormone replacement therapy (HRT): further information on the known increased risk of breast cancer with HRT and its persistence after stopping
- MHRA: Hormone replacement therapy (HRT): further information on the known increased risk of breast cancer with HRT and its persistence after stopping
- MHRA: Hormone replacement therapy (HRT): further information on the known increased risk of breast cancer with HRT and its persistence after stopping
- MHRA: Hormone replacement therapy (HRT): further information on the known increased risk of breast cancer with HRT and its persistence after stopping
- MHRA: Hormone replacement therapy (HRT): further information on the known increased risk of breast cancer with HRT and its persistence after stopping
- MHRA: Hormone replacement therapy (HRT): further information on the known increased risk of breast cancer with HRT and its persistence after stopping
- MHRA: Hormone replacement therapy (HRT): further information on the known increased risk of breast cancer with HRT and its persistence after stopping
- MHRA: Hormone replacement therapy (HRT): further information on the known increased risk of breast cancer with HRT and its persistence after stopping
- MHRA: Hormone replacement therapy (HRT): further information on the known increased risk of breast cancer with HRT and its persistence after stopping
- NHSE guidance to primary care about unregulated providers who supply hormone medications to children and young people for gender incongruence
- NICE NG17: Type 1 diabetes in adults: diagnosis and management
- NICE NG18: Diabetes (type 1 and type 2) in children and young people: diagnosis and management
- NICE NG19: Diabetic foot problems: prevention and management
- NICE NG23: Menopause: identification and management
- NICE NG28: Type 2 diabetes in adults: management
- NICE NG3: Diabetes in pregnancy: management from preconception to the postnatal period
- NICE TA160: Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women
- NICE TA161:Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women